SPA
CRVO icon

Sherbrooke Park Advisers’s CervoMed CRVO Stock Holding History

Sherbrooke Park Advisers’s Portfolio CRVO Stock Details CRVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,766
Closed -$172K – 838
2024
Q3 		$172K Buy
+11,766
New +$182K 0.04% 783

Other funds holding CRVO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PWM
Perigon Wealth Management San Francisco, California $5.51B AUM 24.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Sherbrooke Park Advisers's CRVO Position: Q4 2024 in Review

Sherbrooke Park Advisers sold out of CervoMed (CRVO) in Q4 2024, closing a stake of 11,766 shares — an estimated $172K sold.

Sherbrooke Park Advisers first reported a position in CRVO in Q3 2024 and held it in 1 quarter. The position peaked at $172K in Q3 2024. 49 funds tracked by Wall St. Rank hold CRVO as of Q4 2024.

  • Sherbrooke Park Advisers reported no remaining CervoMed position as of Q4 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 11,766 CervoMed shares in Q4 2024, an estimated $172K.
  • Sherbrooke Park Advisers first reported a position in CervoMed in Q3 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's CervoMed position peaked at $172K in Q3 2024.
  • 49 funds tracked by Wall St. Rank held CervoMed as of Q4 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.